Vindesine

Generic Name: Vindesine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₅N_₅O_₇

CAS Number: 53643-48-4

Unique Ingredient Identifier: RSA8KO39WH

Background: Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).

Indication: For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Blast crisis in myelogenous leukaemia, Malignant Melanoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Not Applicable

Conditions: Lymphoma

First Posted Date: 2006-04-24

Last Posted Date: 2015-09-25

Lead Sponsor: European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma

Target Recruit Count: 96

Registration Number: NCT00317408

Locations: 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪
Krankenhaus Muenchen Schwabing, Munich, Germany

and more 91 locations

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Phase 4

Completed

Conditions: Lymphoma, Lymphoblastic

First Posted Date: 2005-09-20

Last Posted Date: 2010-08-23

Lead Sponsor: Johann Wolfgang Goethe University Hospital

Target Recruit Count: 75

Registration Number: NCT00199017

Locations: 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

First Posted Date: 2005-09-20

Last Posted Date: 2022-08-18

Lead Sponsor: Goethe University

Target Recruit Count: 1883

Registration Number: NCT00198991

Locations: 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Phase 4

Completed

Conditions: Adult Acute Lymphocytic Leukemia

First Posted Date: 2005-09-20

Last Posted Date: 2010-08-23

Lead Sponsor: Johann Wolfgang Goethe University Hospital

Target Recruit Count: 60

Registration Number: NCT00199004

Locations: 🇩🇪
University Hospital of Frankfurt, Medical Dept. II, Frankfurt, Germany

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Phase 2

Completed

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Velcade
Drug: Doxorubicin
Drug: Prednisone
Drug: Cyclophosphamide
Drug: Vindesine
Drug: Bleomycin

First Posted Date: 2005-08-29

Last Posted Date: 2018-08-23

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 60

Registration Number: NCT00136565

Locations: 🇧🇪
Groupe d'Etude des Lymphomes de l'Adulte, Yvoir, Belgium
🇫🇷
Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France
🇫🇷
Centre Hospitalier Robert Debré, Reims, France

and more 2 locations

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Phase 3

Terminated

Conditions: Lymphoma, Large-Cell, Diffuse

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vindesine
Drug: Vincristine
Drug: Bleomycin
Drug: Prednisone

First Posted Date: 2005-08-26

Last Posted Date: 2018-08-23

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 138

Registration Number: NCT00135499

Locations: 🇫🇷
Centre Hospitalier Robert Debré, Reims, France
🇨🇭
Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇧🇪
Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium

and more 5 locations

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

First Posted Date: 2004-05-12

Last Posted Date: 2013-12-19

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 500

Registration Number: NCT00002802

Locations: 🇩🇪
University of Cologne, Frechen, Germany

Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer

Phase 3

Completed

Conditions: Cervical Cancer

First Posted Date: 2004-04-14

Last Posted Date: 2012-07-11

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 700

Registration Number: NCT00003209

Locations: 🇬🇧
Derbyshire Royal Infirmary, Derby, England, United Kingdom
🇬🇧
Beatson Oncology Centre, Glasgow, Scotland, United Kingdom

Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer

Phase 1

Conditions: Lung Cancer

First Posted Date: 2004-03-26

Last Posted Date: 2013-09-17

Lead Sponsor: Ottawa Regional Cancer Centre

Target Recruit Count: 30

Registration Number: NCT00002887

Locations: 🇨🇦
Ottawa Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2004-03-11

Last Posted Date: 2013-03-28

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 3300

Registration Number: NCT00002823

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇸🇮
University of Ljubljana, Ljubljana, Slovenia

and more 120 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy